• FDA Piloting Real-Time Review of Clinical Trial Data From AstraZeneca, Amgen

    Clinical Research News | The U.S. Food & Drug Administration is piloting real-time review of data from AstraZeneca and Amgen clinical trials, both using Paradigm Health's Study Conduct platform, and has issued a call for feedback on how artificial intelligence (AI)-enabled technologies can improve efficiency, speed, and quality of decision-making in early phase clinical trials. FDA has already received and validated signals for AstraZeneca’s trial and expects this to be the first step in implementing real-time clinical trials (RTCT).

    Apr 29, 2026

  • Discovery Life Sciences, Mindpeak Partnership, Streamlining Communications, Rare Disease Referrals

    Clinical Research News | Discovery Life Sciences and Mindpeak enter a partnership; Cenevo has launched the Labguru Customer Portal; myTomorrows and Rare Disease Research team up; and more.

    Apr 28, 2026

  • Lung Cancer Trial Trends Show Geographic Concentration

    Clinical Research News | In research presented this week at the American Association for Cancer Research (AACR) Annual Meeting, trends surfaced showing that between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 highest‑volume clinical trial sites largely located in major cities.

    Apr 23, 2026

  • Pistoia Alliance Furthers Research on Using Social Media Listening in Drug Discovery, Clinical Research

    Clinical Research News | In an expansion of its advocacy work into clinical fields, the Pistoia Alliance has launched new patient research to shape the ethical use of social media listening in drug development. The work is part of its ongoing Social Media Real-World Evidence (RWE) project.

    Apr 22, 2026

  • Veristat Discovers a Goldmine of Opportunities in China

    Clinical Research News | Following an eye-opening experience at China’s largest biotechnology and life sciences event, Veristat is positioning itself as a first mover in accommodating the regulatory needs of multiple Chinese companies eager to enter European and North American markets. The shift comes in response to government policy reforms over the past decade, with purpose-built R&D cities and science parks in more recent years acting as physical accelerators.

    Apr 16, 2026

  • Cautious Optimism About FDA’s One Pivotal Trial Policy

    Clinical Research News | Earlier this year, the U.S. Food and Drug Administration (FDA) made a single pivotal clinical trial the default requirement for getting a medicine to market in lieu of the traditional two-trial mandate. It was a controversial move designed to reduce clinical development costs for drug sponsors, but it comes with the peril of potential project failure if study results aren’t rigorously defensible—or if companies fail to invest heavily in the quality of that single trial using readily accessible tools for data monitoring, artificial intelligence (AI), and biosimulation.

    Apr 14, 2026

  • AI in the Clinical Space: What 2030 Looks Like

    Clinical Research News | Clinical research is entering a phase where “using AI” is no longer the headline, and redesigning clinical operations becomes the real work. Mike Sullivan, head of IT globally for development operations at Bristol Myers Squibb, joins The Scope of Things to discuss a persistent industry problem: clinical insight latency, the long delay between data being generated at sites and meaningful decisions being made by sponsors.

    Apr 9, 2026